Aptose Biosciences, Inc. (APTO) Receives $4.50 Consensus Target Price from Brokerages

Aptose Biosciences, Inc. (NASDAQ:APTO) (TSE:APS) has been assigned an average rating of “Buy” from the six analysts that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have given a buy recommendation to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $4.50.

A number of analysts have recently commented on the company. ValuEngine cut Aptose Biosciences from a “sell” rating to a “strong sell” rating in a research report on Friday. Roth Capital restated a “buy” rating and issued a $5.00 price objective on shares of Aptose Biosciences in a research report on Monday, October 23rd. Zacks Investment Research upgraded Aptose Biosciences from a “hold” rating to a “buy” rating and set a $1.50 price objective for the company in a research report on Monday, August 14th. HC Wainwright upgraded Aptose Biosciences from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $1.00 to $4.00 in a research report on Thursday, September 7th. Finally, Canaccord Genuity set a $7.00 price objective on Aptose Biosciences and gave the company a “buy” rating in a research report on Wednesday, November 15th.

Aptose Biosciences (NASDAQ:APTO) traded down $0.12 during trading on Friday, hitting $1.89. The stock had a trading volume of 296,131 shares, compared to its average volume of 393,144. Aptose Biosciences has a 1-year low of $0.78 and a 1-year high of $2.30.

COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by Week Herald and is the property of of Week Herald. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The legal version of this piece of content can be read at https://weekherald.com/2017/12/05/aptose-biosciences-inc-apto-receives-4-50-consensus-target-price-from-brokerages.html.

Aptose Biosciences Company Profile

Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.

Receive News & Ratings for Aptose Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply